Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

Gastroenterology(2022)10.1053/j.gastro.2022.06.052Source: DataRank Database

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis is a research paper published in Gastroenterology (2022). On theSindex it has a DataRank of 0. It has been cited 69 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

69 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 4.54)OA: closedTopics (23)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Virginia Solitano ORCID,Sudheer K. Vuyyuru ORCID,John K MacDonald,Silje Watterdal Syversen ORCID,Kristin Kaasen Jørgensen ORCID

Live enrichment

PubMed:35753383 OpenAlex:https://openalex.org/W4283397805

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: K23DK117058

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: R03DK129631

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: T32DK007202

Patient-Centered Outcomes Research Institute

Grant: CER-2020C3-21024

U.S. National Library of Medicine

Grant: T15LM011271

AbbVie

Janssen Pharmaceuticals

Roche

Pfizer

Ferring Pharmaceuticals

FWCI

4.54

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S0016508522006709?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0016508522006709?httpAccept=text/plain

journalhttps://doi.org/10.1053/j.gastro.2022.06.052

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35753383

Fields of Study

Inflammatory Bowel DiseaseBiosimilars and Bioanalytical MethodsRheumatoid Arthritis Research and Therapies

MeSH Terms

AdultBiological ProductsHumansRemission InductionTumor Necrosis Factor-alphaInflammatory Bowel DiseasesDrug Monitoring

Keywords

Meta-analysisMedicineInflammatory Bowel DiseasesTherapeutic drug monitoringDrugIntensive care medicineInflammatory bowel diseaseInternal medicinePharmacologyOptimizationBiologicsTreatment StrategyTrough

Sustainable Development Goals

SDG 0: Good health and well-being

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

FAIR Checklist

Authors (10)

Funding (10 grants)

Impact

Open Access

Topics